Psychedelics and other psychoplastogens for treating mental illness

MV Vargas, R Meyer, AA Avanes, M Rus… - Frontiers in …, 2021 - frontiersin.org
Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

Molecular mechanisms of psilocybin and implications for the treatment of depression

S Ling, F Ceban, LMW Lui, Y Lee, KM Teopiz… - CNS drugs, 2022 - Springer
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

RS McIntyre, M Alsuwaidan, BT Baune, M Berk… - World …, 2023 - Wiley Online Library
Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

[HTML][HTML] Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of …

GM Goodwin, ST Aaronson, O Alvarez, M Atli… - Journal of Affective …, 2023 - Elsevier
Background COMP360 is a proprietary, synthetic formulation of psilocybin being developed
for treatment-resistant depression (TRD), a burdensome, life-threatening illness with high …

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study

N Zaki, L Chen, R Lane, T Doherty… - …, 2023 - nature.com
Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …

Treatment-resistant depression: approaches to treatment

KS Kverno, E Mangano - Journal of psychosocial nursing and …, 2021 - journals.healio.com
Approximately 30% of people treated for a major depressive episode will not achieve
remission after two or more treatment trials of first-line antidepressants and are considered …

Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)

G Martinotti, A Vita, A Fagiolini, G Maina… - Journal of Affective …, 2022 - Elsevier
Abstract Background Treatment-resistant Depression (TRD) represents a widespread
disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer …

Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action

LP Cameron, J Benetatos, V Lewis… - Journal of …, 2023 - Soc Neuroscience
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention
in recent years for their potential therapeutic effects and unique mechanisms of action …

Pharmacotherapies for treatment-resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape

MK Jha, SJ Mathew - American Journal of Psychiatry, 2023 - Am Psychiatric Assoc
One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Mechanisms for survival: Vagal control of goal-directed behavior

V Teckentrup, NB Kroemer - Trends in Cognitive Sciences, 2024 - cell.com
Survival is a fundamental physiological drive, and neural circuits have evolved to prioritize
actions that meet the energy demands of the body. This fine-tuning of goal-directed actions …